
JPMorgan raised the firm’s price target on Septerna (SEPN) to $51 from $48 and keeps an Overweight rating on the shares post the Q3 report. Published first on TheFly –
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| SEPN | Septerna, Inc. | 38.61 | 13.05 | 51.06% |
| Name | Price | % Change | |
|---|---|---|---|
| $38.61 | +51.06% |

JPMorgan raised the firm’s price target on Septerna (SEPN) to $51 from $48 and keeps an Overweight rating on the shares post the Q3 report. Published first on TheFly –

Septerna (SEPN) is down -9.4%, or -$4.94 to $47.40. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on

Stifel raised the firm’s price target on Septerna (SEPN) to $60 from $49 and keeps a Buy rating on the shares. Published first on TheFly – the ultimate source for

Guggenheim analyst Seamus Fernandez raised the firm’s price target on Septerna (SEPN) to $65 from $51 and keeps a Buy rating on the shares, citing a belief that the company

Septerna, Inc. ( ($SEPN) ) just unveiled an update. Septerna is a clinical-stage biotechnology company advancing oral small-molecule GPCR drug candidates through its Native Complex Platform, with programs spanning endocrinology,

Wells Fargo raised the firm’s price target on Septerna (SEPN) to $61 from $50 and keeps an Overweight rating on the shares following a SEP-479 deep dive. The firm’s cross-program,

Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Progress Software ($PRGS), and AngioDynamics ($ANGO) as companies with solid fundamentals

While many investors remain focused on large-cap stocks, some smaller companies could offer greater upside potential. Analysts are bullish on several small-cap stocks with solid fundamentals. Using TipRanks’ Stock Screener,

An announcement from Septerna, Inc. ( ($SEPN) ) is now available. Septerna, Inc., a clinical-stage biotechnology company specializing in GPCR-targeted oral small-molecule therapies for unmet needs in endocrinology, immunology, inflammation

JPMorgan raised the firm’s price target on Septerna (SEPN) to $48 from $38 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | Nov 19, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 10, 2026 | ||||
| buy | Reiterated | Nov 9, 2026 | ||||
| buy | Assigned | Nov 6, 2026 | ||||
| buy | Reiterated | Aug 13, 2026 | ||||
| buy | Reiterated | Aug 11, 2026 | ||||
| buy | Assigned | Aug 11, 2026 | ||||
| buy | Reiterated | Mar 2, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $1.84B | $-0.45 | $24.76M | 0.59 | -29.93 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.